Generic Medicines Groups Oppose Changes to Biologic Exclusivity in US-Mexico Trade Deal
An extension of brand name biologic data protections to 10 years "will harm patients who seek more affordable medicines," the Association for Accessible Medicines, the Canadian Generic Pharmaceutical Association, and the Mexican Association of Generic Medicines said in a joint…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
statement. "The U.S., Mexico and Canada should reject these provisions, which would benefit brand name drug companies to the detriment of public health and the affordability of medical care," the groups said. The extended protections are part of the deal's intellectual property chapter, the Office of the U.S. Trade Representative said in a fact sheet.